CoChat
Sign Up
Cited by 101Cancer Cells and MetastasisTGF-β signaling in diseasesAngiogenesis and VEGF in Cancer

The DOI matches its Crossref record; 130 of the 131 references it cites were found in a registry or an index.

Endothelial-to-Mesenchymal Transition (EndoMT): Roles in Tumorigenesis, Metastatic Extravasation and Therapy Resistance

Open access
Platel, Valentin, Faure, Sébastien, Corre, Isabelle, Clere, Nicolas·2019·Journal of Oncology
DOI 10.1155/2019/8361945PMC PMC6701373
Open this paper in CoChat — free accountOpen PDF

Abstract

Cancer cells evolve in a very complex tumor microenvironment, composed of several cell types, among which the endothelial cells are the major actors of the tumor angiogenesis. Today, these cells are also characterized for their plasticity, as endothelial cells have demonstrated their potential to modify their phenotype to differentiate into mesenchymal cells through the endothelial-to-mesenchymal transition (EndoMT). This cellular plasticity is mediated by various stimuli including transforming growth factor-β (TGF-β) and is modulated dependently of experimental conditions. Recently, emerging evidences have shown that EndoMT is involved in the development and dissemination of cancer and also in cancer cell to escape from therapeutic treatment. In this review, we summarize current updates on EndoMT and its main induction pathways. In addition, we discuss the role of EndoMT in tumorigenesis, metastasis, and its potential implication in cancer therapy resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2019/8361945

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Phenotypic modifications during EndoMT. TGF-β (transforming growth factor-β); ROS (reactive oxygen species); VE cadherin (vascular endothelial cadherin); vWF (vonWillebrand factor); FSP-1 (fibroblast-specific protein-1); α-SMA (α-smooth muscle actin).
Figure 1 Phenotypic modifications during EndoMT. TGF-β (transforming growth factor-β); ROS (reactive oxygen species); VE cadherin (vascular endothelial cadherin); vWF (vonWillebrand factor); FSP-1 (fibroblast-specific protein-1); α-SMA (α-smooth muscle actin).CC BY · PubMed Central
Figure 2 Transforming growth factor-β- (TGF-β-) induced EndoMT. Upon stimulation by TGF-β1, -2, or -3, type-2 TGF-β receptors phosphorylate ALK5 (type-1 TGF-B receptor) and associate into a heterotetrameric structure which induce Smad-2/3/4 complex formation and translocation to the nucleus. Stimulation by TGF-β1 or -3 induces a paracrine loop toward a TGF-β2 stimulation. Smad-7 acts as an inhibitor of Smad association and serves as a negative retro control. TGF-β signaling also induces phosphorylation of ERK 1/2 (extracellular signal-regulated kinases 1/2) and p38 MAPK (p38 mitogen-activated protein kinase). The BMP receptors can also trigger upon stimulation by the BMP ligand canonical Smad pathway and non-canonical ERK pathway. Inside the nucleus, all actors involved stimulate the activity of the transcription factor, mainly Snail, Slug, and Twist, thus initiating EndoMT by promoting transcription of mesenchymal markers and diminishing transcription of endothelial markers. TGF-β signaling crosstalk with several others pathways, including Notch which promotes ERK 1/2 activity and Akt2 isoform activity which will then inhibit GSK-3β. GSK-3β, ERK, PI3K, P38, and also CDK4 can phosphorylate Smad-2 and -3 on specific residues in its linker region (in red) promoting Smad signaling in a canonical-independent manner. However, it is worth to note that some studies report the inhibiting effect of linker region phosphorylation, and that the specific effects of this phosphorylation site seem to be cell-type dependent.
Figure 2 Transforming growth factor-β- (TGF-β-) induced EndoMT. Upon stimulation by TGF-β1, -2, or -3, type-2 TGF-β receptors phosphorylate ALK5 (type-1 TGF-B receptor) and associate into a heterotetrameric structure which induce Smad-2/3/4 complex formation and translocation to the nucleus. Stimulation by TGF-β1 or -3 induces a paracrine loop toward a TGF-β2 stimulation. Smad-7 acts as an inhibitor of Smad association and serves as a negative retro control. TGF-β signaling also induces phosphorylation of ERK 1/2 (extracellular signal-regulated kinases 1/2) and p38 MAPK (p38 mitogen-activated protein kinase). The BMP receptors can also trigger upon stimulation by the BMP ligand canonical Smad pathway and non-canonical ERK pathway. Inside the nucleus, all actors involved stimulate the activity of the transcription factor, mainly Snail, Slug, and Twist, thus initiating EndoMT by promoting transcription of mesenchymal markers and diminishing transcription of endothelial markers. TGF-β signaling crosstalk with several others pathways, including Notch which promotes ERK 1/2 activity and Akt2 isoform activity which will then inhibit GSK-3β. GSK-3β, ERK, PI3K, P38, and also CDK4 can phosphorylate Smad-2 and -3 on specific residues in its linker region (in red) promoting Smad signaling in a canonical-independent manner. However, it is worth to note that some studies report the inhibiting effect of linker region phosphorylation, and that the specific effects of this phosphorylation site seem to be cell-type dependent.CC BY · PubMed Central
Figure 3 Wnt induction of EndoMT. Wnt bound the extracellular part of the Frizzled receptor, while LRP5/6 serves as co-receptors. This causes the complex Axin-GSK-3β to bind to the cytoplasmic tail of LRP5/6. Therefore, this complex is no longer able to assure the degradation of β-catenin, which accumulates in the cytoplasm and translocates into the nucleus to stimulate the activity of transcription factors of the TCF/LEF families. The Wnt pathway crosstalk with several other pathways: Akt 2 can phosphorylate and thus inhibit GSK-3β. Moreover, RSK phosphorylation ERK 1/2-dependent RSK phosphorylation leads to inhibition of GSK-3β.
Figure 3 Wnt induction of EndoMT. Wnt bound the extracellular part of the Frizzled receptor, while LRP5/6 serves as co-receptors. This causes the complex Axin-GSK-3β to bind to the cytoplasmic tail of LRP5/6. Therefore, this complex is no longer able to assure the degradation of β-catenin, which accumulates in the cytoplasm and translocates into the nucleus to stimulate the activity of transcription factors of the TCF/LEF families. The Wnt pathway crosstalk with several other pathways: Akt 2 can phosphorylate and thus inhibit GSK-3β. Moreover, RSK phosphorylation ERK 1/2-dependent RSK phosphorylation leads to inhibition of GSK-3β.CC BY · PubMed Central
Figure 4 Notch induction of EndoMT. Notch receptors' family interacts with diverse ligands via a cell-to-cell contact mechanism. The signal is mediated by the Notch intracellular domain (NICD) through the nucleus to activate a complex of inducers (RBPJ/CBF1/Su(H)) which in turn activates the transcription of genes implicated in EndoMT. This complex also stabilizes the Snail protein. The Notch pathway crosstalks with several other pathways: NICD increases the Akt 2 expression which inhibits GSK-3β. NICD also activates ERK 1/2, which activates RSK leading to GSK-3β downregulation. The nuclear Notch complex also interacts with β-catenin, increasing its transcription activity.
Figure 4 Notch induction of EndoMT. Notch receptors' family interacts with diverse ligands via a cell-to-cell contact mechanism. The signal is mediated by the Notch intracellular domain (NICD) through the nucleus to activate a complex of inducers (RBPJ/CBF1/Su(H)) which in turn activates the transcription of genes implicated in EndoMT. This complex also stabilizes the Snail protein. The Notch pathway crosstalks with several other pathways: NICD increases the Akt 2 expression which inhibits GSK-3β. NICD also activates ERK 1/2, which activates RSK leading to GSK-3β downregulation. The nuclear Notch complex also interacts with β-catenin, increasing its transcription activity.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 131 references

Cited by

Sorted by citations

See all 101

Related

Metadata

Authors
Platel, V., Faure, S., Corre, I., & Clere, N.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Inserm (FR)
Corresponding author
  • Corre, Isabelle
  • Clere, Nicolas
ORCID
Venue
Journal of Oncology
Publisher
Wiley
Published
2019-08-01
Volume
2019
Pages
1-13
ISSN
  • 1687-8450 (ISSN-L)
  • 1687-8469
DOI
10.1155/2019/8361945
PMC
PMC6701373
OpenAlex
W2953419714
Cited by
101
References
131
Citations by year
2026: 2 · 2025: 14 · 2024: 16 · 2023: 17 · 2022: 14 · 2021: 18 · 2020: 16 · 2019: 2
FWCI
1.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Région Pays de la Loire
  • Comité départemental du Maine et Loire de la Ligue contre le Cancer
  • Comité départemental de Loire Atlantique de la Ligue contre le Cancer
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
endothelial-to-mesenchymal transition, endothelial cells, cellular plasticity, carcinogenesis, metastasis, cancer therapy resistance, tumor microenvironment, tumor angiogenesis, TGF-beta, mesenchymal differentiation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review